1. In Vivo
  2. >>Leadership

How Novo Revitalized Its Rare Disease Operations

 
• By Kevin Grogan

There is more to the Danish major than diabetes and Ludovic Helfgott gave In Vivo an insight to the firm’s ambitious plans for its renamed rare diseases division.

Ludovic Helfgott
Ludovic Helfgott • Source: Novo Nordisk

Novo Nordisk A/S may be best known for its diabetes and obesity businesses, but the Danish group is determined to make its presence more keenly felt in the rare diseases space; an area in which it has been active for over four decades.

The Copenhagen-headquartered group announced at a recent capital markets day that it has changed the name of its biopharm franchise...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.